Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 53 entries
Sorted by: Best Match Show Resources per page
[Not Available].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie

Dariane C, Pasqualini C, Gaspar N, Brugieres L, Patte C, Arfi-Rouche J, Patard J, Baumert H, Loriot Y, Massard C, Fizazi K, Merabet Z, Di Palma M, Escudier B, Albiges L.
PMID: 26544360
Prog Urol. 2015 Nov;25(13):798-9. doi: 10.1016/j.purol.2015.08.165.

No abstract available.

Cite
Dariane C, Pasqualini C, Gaspar N, et al. Tumeurs rénales du sujet jeune : expérience monocentrique. [Not Available]. Prog Urol. 2015;25(13):798-9doi: 10.1016/j.purol.2015.08.165.
Dariane, C., Pasqualini, C., Gaspar, N., Brugieres, L., Patte, C., Arfi-Rouche, J., Patard, J., Baumert, H., Loriot, Y., Massard, C., Fizazi, K., Merabet, Z., Di Palma, M., Escudier, B., & Albiges, L. (2015). Tumeurs rénales du sujet jeune : expérience monocentrique. [Not Available]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 25(13), 798-9. https://doi.org/10.1016/j.purol.2015.08.165
Dariane, C, et al. "Tumeurs rénales du sujet jeune : expérience monocentrique." [Not Available]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie vol. 25,13 (2015): 798-9. doi: https://doi.org/10.1016/j.purol.2015.08.165
Dariane C, Pasqualini C, Gaspar N, Brugieres L, Patte C, Arfi-Rouche J, Patard J, Baumert H, Loriot Y, Massard C, Fizazi K, Merabet Z, Di Palma M, Escudier B, Albiges L. Tumeurs rénales du sujet jeune : expérience monocentrique. [Not Available]. Prog Urol. 2015 Nov;25(13):798-9. doi: 10.1016/j.purol.2015.08.165. French. PMID: 26544360.
Copy Download .nbib Format: NLM
Fatal invasive aspergillosis caused by .

Medical mycology case reports

Atchade E, Jean-Baptiste S, Houzé S, Chabut C, Massias L, Castier Y, Brugière O, Mal H, Montravers P.
PMID: 28560131
Med Mycol Case Rep. 2017 May 18;17:4-7. doi: 10.1016/j.mmcr.2017.05.002. eCollection 2017 Sep.

No abstract available.

Cite
Atchade E, Jean-Baptiste S, Houzé S, et al. Fatal invasive aspergillosis caused by . Med Mycol Case Rep. 2017;17:4-7doi: 10.1016/j.mmcr.2017.05.002.
Atchade, E., Jean-Baptiste, S., Houzé, S., Chabut, C., Massias, L., Castier, Y., Brugière, O., Mal, H., & Montravers, P. (2017). Fatal invasive aspergillosis caused by . Medical mycology case reports, 174-7. https://doi.org/10.1016/j.mmcr.2017.05.002
Atchade, Enora, et al. "Fatal invasive aspergillosis caused by ." Medical mycology case reports vol. 17 (2017): 4-7. doi: https://doi.org/10.1016/j.mmcr.2017.05.002
Atchade E, Jean-Baptiste S, Houzé S, Chabut C, Massias L, Castier Y, Brugière O, Mal H, Montravers P. Fatal invasive aspergillosis caused by . Med Mycol Case Rep. 2017 May 18;17:4-7. doi: 10.1016/j.mmcr.2017.05.002. eCollection 2017 Sep. PMID: 28560131; PMCID: PMC5443963.
Copy Download .nbib Format: NLM
Corrigendum: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.

Nature

Bertolotto C, Lesueur F, Giuliano S, Strub T, de Lichy M, Bille K, Dessen P, d'Hayer B, Mohamdi H, Remenieras A, Maubec E, de la Fouchardière A, Molinié V, Vabres P, Dalle S, Poulalhon N, Martin-Denavit T, Thomas L, Andry-Benzaquen P, Dupin N, Boitier F, Rossi A, Perrot JL, Labeille B, Robert C, Escudier B, Caron O, Brugières L, Saule S, Gardie B, Gad S, Richard S, Couturier J, Teh BT, Ghiorzo P, Pastorino L, Puig S, Badenas C, Olsson H, Ingvar C, Rouleau E, Lidereau R, Bahadoran P, Vielh P, Corda E, Blanché H, Zelenika D, Galan P, Chaudru V, Lenoir GM, Lathrop M, Davidson I, Avril MF, Demenais F, Ballotti R, Bressac-de Paillerets B.
PMID: 26633630
Nature. 2016 Mar 03;531(7592):126. doi: 10.1038/nature16158. Epub 2015 Dec 02.

No abstract available.

Cite
Bertolotto C, Lesueur F, Giuliano S, et al. Corrigendum: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature. 2015;531(7592):126doi: 10.1038/nature16158.
Bertolotto, C., Lesueur, F., Giuliano, S., Strub, T., de Lichy, M., Bille, K., Dessen, P., d'Hayer, B., Mohamdi, H., Remenieras, A., Maubec, E., de la Fouchardière, A., Molinié, V., Vabres, P., Dalle, S., Poulalhon, N., Martin-Denavit, T., Thomas, L., Andry-Benzaquen, P., Dupin, N., Boitier, F., Rossi, A., Perrot, J. L., Labeille, B., Robert, C., Escudier, B., Caron, O., Brugières, L., Saule, S., Gardie, B., Gad, S., Richard, S., Couturier, J., Teh, B. T., Ghiorzo, P., Pastorino, L., Puig, S., Badenas, C., Olsson, H., Ingvar, C., Rouleau, E., Lidereau, R., Bahadoran, P., Vielh, P., Corda, E., Blanché, H., Zelenika, D., Galan, P., Chaudru, V., Lenoir, G. M., Lathrop, M., Davidson, I., Avril, M. F., Demenais, F., Ballotti, R., & Bressac-de Paillerets, B. (2016). Corrigendum: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature, 531(7592), 126. https://doi.org/10.1038/nature16158
Bertolotto, Corine, et al. "Corrigendum: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma." Nature vol. 531,7592 (2016): 126. doi: https://doi.org/10.1038/nature16158
Bertolotto C, Lesueur F, Giuliano S, Strub T, de Lichy M, Bille K, Dessen P, d'Hayer B, Mohamdi H, Remenieras A, Maubec E, de la Fouchardière A, Molinié V, Vabres P, Dalle S, Poulalhon N, Martin-Denavit T, Thomas L, Andry-Benzaquen P, Dupin N, Boitier F, Rossi A, Perrot JL, Labeille B, Robert C, Escudier B, Caron O, Brugières L, Saule S, Gardie B, Gad S, Richard S, Couturier J, Teh BT, Ghiorzo P, Pastorino L, Puig S, Badenas C, Olsson H, Ingvar C, Rouleau E, Lidereau R, Bahadoran P, Vielh P, Corda E, Blanché H, Zelenika D, Galan P, Chaudru V, Lenoir GM, Lathrop M, Davidson I, Avril MF, Demenais F, Ballotti R, Bressac-de Paillerets B. Corrigendum: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature. 2016 Mar 03;531(7592):126. doi: 10.1038/nature16158. Epub 2015 Dec 02. PMID: 26633630.
Copy Download .nbib Format: NLM
Liver magnetic resonance diffusion weighted imaging: 2011 update.

Clinics and research in hepatology and gastroenterology

Chiaradia M, Baranes L, Pigneur F, Djabbari M, Zegai B, Brugières P, Zerbib P, Decaens T, Deux JF, Kobeiter H, Rahmouni A, Luciani A.
PMID: 21700529
Clin Res Hepatol Gastroenterol. 2011 Sep;35(8):539-48. doi: 10.1016/j.clinre.2011.05.001. Epub 2011 Jun 22.

Diffusion-Weighted-Imaging (DWI) assesses proton motion on a cellular scale. Owing to recent instrumentation developments, diffusion sequences are now routinely used for liver imaging. This review will go through the physical principles that underlie this technique, and then highlight up-to-date...

Cite
Chiaradia M, Baranes L, Pigneur F, et al. Liver magnetic resonance diffusion weighted imaging: 2011 update. Clin Res Hepatol Gastroenterol. 2011;35(8):539-48doi: 10.1016/j.clinre.2011.05.001.
Chiaradia, M., Baranes, L., Pigneur, F., Djabbari, M., Zegai, B., Brugières, P., Zerbib, P., Decaens, T., Deux, J. F., Kobeiter, H., Rahmouni, A., & Luciani, A. (2011). Liver magnetic resonance diffusion weighted imaging: 2011 update. Clinics and research in hepatology and gastroenterology, 35(8), 539-48. https://doi.org/10.1016/j.clinre.2011.05.001
Chiaradia, Mélanie, et al. "Liver magnetic resonance diffusion weighted imaging: 2011 update." Clinics and research in hepatology and gastroenterology vol. 35,8 (2011): 539-48. doi: https://doi.org/10.1016/j.clinre.2011.05.001
Chiaradia M, Baranes L, Pigneur F, Djabbari M, Zegai B, Brugières P, Zerbib P, Decaens T, Deux JF, Kobeiter H, Rahmouni A, Luciani A. Liver magnetic resonance diffusion weighted imaging: 2011 update. Clin Res Hepatol Gastroenterol. 2011 Sep;35(8):539-48. doi: 10.1016/j.clinre.2011.05.001. Epub 2011 Jun 22. PMID: 21700529.
Copy Download .nbib Format: NLM
High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group.

Sarcoma

Marec-Berard P, Segura-Ferlay C, Tabone MD, Pacquement H, Lervat C, Gentet JC, Schmitt C, Gaspar N, Brugières L.
PMID: 24672280
Sarcoma. 2014;2014:475067. doi: 10.1155/2014/475067. Epub 2014 Feb 04.

Introduction. Osteosarcoma relapse has a poor prognosis, with less than 25% survival at 5 years. We describe the experience of the French Society of Paediatric Oncology (SFCE) with high dose (HD) thiotepa and autologous stem cell transplantation (ASCT) in...

Cite
Marec-Berard P, Segura-Ferlay C, Tabone MD, et al. High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group. Sarcoma. 2014;2014:475067doi: 10.1155/2014/475067.
Marec-Berard, P., Segura-Ferlay, C., Tabone, M. D., Pacquement, H., Lervat, C., Gentet, J. C., Schmitt, C., Gaspar, N., & Brugières, L. (2014). High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group. Sarcoma, 2014475067. https://doi.org/10.1155/2014/475067
Marec-Berard, Perrine, et al. "High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group." Sarcoma vol. 2014 (2014): 475067. doi: https://doi.org/10.1155/2014/475067
Marec-Berard P, Segura-Ferlay C, Tabone MD, Pacquement H, Lervat C, Gentet JC, Schmitt C, Gaspar N, Brugières L. High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group. Sarcoma. 2014;2014:475067. doi: 10.1155/2014/475067. Epub 2014 Feb 04. PMID: 24672280; PMCID: PMC3941142.
Copy Download .nbib Format: NLM
No Overt Clinical Immunodeficiency Despite Immune Biological Abnormalities in Patients With Constitutional Mismatch Repair Deficiency.

Frontiers in immunology

Tesch VK, IJspeert H, Raicht A, Rueda D, Dominguez-Pinilla N, Allende LM, Colas C, Rosenbaum T, Ilencikova D, Baris HN, Nathrath MHM, Suerink M, Januszkiewicz-Lewandowska D, Ragab I, Azizi AA, Wenzel SS, Zschocke J, Schwinger W, Kloor M, Blattmann C, Brugieres L, van der Burg M, Wimmer K, Seidel MG.
PMID: 30013564
Front Immunol. 2018 Jul 02;9:1506. doi: 10.3389/fimmu.2018.01506. eCollection 2018.

Immunoglobulin class-switch recombination (CSR) and somatic hypermutations (SHMs) are prerequisites for antibody and immunoglobulin receptor maturation and adaptive immune diversity. The mismatch repair (MMR) machinery, consisting of homologs of MutSα, MutLα, and MutSβ (MSH2/MSH6, MLH1/PMS2, and MSH2/MSH3, respectively) and...

Cite
Tesch VK, IJspeert H, Raicht A, et al. No Overt Clinical Immunodeficiency Despite Immune Biological Abnormalities in Patients With Constitutional Mismatch Repair Deficiency. Front Immunol. 2018;9:1506doi: 10.3389/fimmu.2018.01506.
Tesch, V. K., IJspeert, H., Raicht, A., Rueda, D., Dominguez-Pinilla, N., Allende, L. M., Colas, C., Rosenbaum, T., Ilencikova, D., Baris, H. N., Nathrath, M. H. M., Suerink, M., Januszkiewicz-Lewandowska, D., Ragab, I., Azizi, A. A., Wenzel, S. S., Zschocke, J., Schwinger, W., Kloor, M., Blattmann, C., Brugieres, L., van der Burg, M., Wimmer, K., & Seidel, M. G. (2018). No Overt Clinical Immunodeficiency Despite Immune Biological Abnormalities in Patients With Constitutional Mismatch Repair Deficiency. Frontiers in immunology, 91506. https://doi.org/10.3389/fimmu.2018.01506
Tesch, Victoria K, et al. "No Overt Clinical Immunodeficiency Despite Immune Biological Abnormalities in Patients With Constitutional Mismatch Repair Deficiency." Frontiers in immunology vol. 9 (2018): 1506. doi: https://doi.org/10.3389/fimmu.2018.01506
Tesch VK, IJspeert H, Raicht A, Rueda D, Dominguez-Pinilla N, Allende LM, Colas C, Rosenbaum T, Ilencikova D, Baris HN, Nathrath MHM, Suerink M, Januszkiewicz-Lewandowska D, Ragab I, Azizi AA, Wenzel SS, Zschocke J, Schwinger W, Kloor M, Blattmann C, Brugieres L, van der Burg M, Wimmer K, Seidel MG. No Overt Clinical Immunodeficiency Despite Immune Biological Abnormalities in Patients With Constitutional Mismatch Repair Deficiency. Front Immunol. 2018 Jul 02;9:1506. doi: 10.3389/fimmu.2018.01506. eCollection 2018. PMID: 30013564; PMCID: PMC6036136.
Copy Download .nbib Format: NLM
Adrenocortical tumours in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations.

Pediatric blood & cancer

Virgone C, Roganovic J, Vorwerk P, Redlich A, Schneider DT, Janic D, Bien E, López-Almaraz R, Godzinski J, Osterlundh G, Stachowicz-Stencel T, Brugières L, Brecht IB, Thomas-Teinturier C, Fresneau B, Surun A, Ferrari A, Bisogno G, Orbach D.
PMID: 34174161
Pediatr Blood Cancer. 2021 Jun;68:e29025. doi: 10.1002/pbc.29025.

Adrenocortical tumours (ACTs) are rare during childhood. A complete surgical resection provides the best chance of cure, but the role and efficacy of the adjuvant therapy are still controversial. Various histologic criteria of malignancy for ACTs adopted in children...

Cite
Virgone C, Roganovic J, Vorwerk P, et al. Adrenocortical tumours in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations. Pediatr Blood Cancer. 2021;68:e29025doi: 10.1002/pbc.29025.
Virgone, C., Roganovic, J., Vorwerk, P., Redlich, A., Schneider, D. T., Janic, D., Bien, E., López-Almaraz, R., Godzinski, J., Osterlundh, G., Stachowicz-Stencel, T., Brugières, L., Brecht, I. B., Thomas-Teinturier, C., Fresneau, B., Surun, A., Ferrari, A., Bisogno, G., & Orbach, D. (2021). Adrenocortical tumours in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations. Pediatric blood & cancer, 68e29025. https://doi.org/10.1002/pbc.29025
Virgone, Calogero, et al. "Adrenocortical tumours in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations." Pediatric blood & cancer vol. 68 (2021): e29025. doi: https://doi.org/10.1002/pbc.29025
Virgone C, Roganovic J, Vorwerk P, Redlich A, Schneider DT, Janic D, Bien E, López-Almaraz R, Godzinski J, Osterlundh G, Stachowicz-Stencel T, Brugières L, Brecht IB, Thomas-Teinturier C, Fresneau B, Surun A, Ferrari A, Bisogno G, Orbach D. Adrenocortical tumours in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations. Pediatr Blood Cancer. 2021 Jun;68:e29025. doi: 10.1002/pbc.29025. PMID: 34174161.
Copy Download .nbib Format: NLM
Disease progression in patients with the restrictive and mixed phenotype of Chronic Lung Allograft dysfunction-A retrospective analysis in five European centers to assess the feasibility of a therapeutic trial.

PloS one

Gottlieb J, Verleden GM, Perchl M, Valtin C, Vallee A, Brugière O, Bravo C.
PMID: 34941934
PLoS One. 2021 Dec 23;16(12):e0260881. doi: 10.1371/journal.pone.0260881. eCollection 2021.

BACKGROUND: Chronic Lung Allograft Dysfunction (CLAD) is a major obstacle for long term survival after lung transplantation (LTx). Besides Bronchiolitis Obliterans Syndrome, two other phenotypes of CLAD, restrictive allograft syndrome (RAS) and mixed phenotype, have been described. Trials to...

Cite
Gottlieb J, Verleden GM, Perchl M, et al. Disease progression in patients with the restrictive and mixed phenotype of Chronic Lung Allograft dysfunction-A retrospective analysis in five European centers to assess the feasibility of a therapeutic trial. PLoS One. 2021;16(12):e0260881doi: 10.1371/journal.pone.0260881.
Gottlieb, J., Verleden, G. M., Perchl, M., Valtin, C., Vallee, A., Brugière, O., & Bravo, C. (2021). Disease progression in patients with the restrictive and mixed phenotype of Chronic Lung Allograft dysfunction-A retrospective analysis in five European centers to assess the feasibility of a therapeutic trial. PloS one, 16(12), e0260881. https://doi.org/10.1371/journal.pone.0260881
Gottlieb, Jens, et al. "Disease progression in patients with the restrictive and mixed phenotype of Chronic Lung Allograft dysfunction-A retrospective analysis in five European centers to assess the feasibility of a therapeutic trial." PloS one vol. 16,12 (2021): e0260881. doi: https://doi.org/10.1371/journal.pone.0260881
Gottlieb J, Verleden GM, Perchl M, Valtin C, Vallee A, Brugière O, Bravo C. Disease progression in patients with the restrictive and mixed phenotype of Chronic Lung Allograft dysfunction-A retrospective analysis in five European centers to assess the feasibility of a therapeutic trial. PLoS One. 2021 Dec 23;16(12):e0260881. doi: 10.1371/journal.pone.0260881. eCollection 2021. PMID: 34941934.
Copy Download .nbib Format: NLM
Characterization of Macrophages and Osteoclasts in the Osteosarcoma Tumor Microenvironment at Diagnosis: New Perspective for Osteosarcoma Treatment?.

Cancers

Gomez-Brouchet A, Gilhodes J, Acker NV, Brion R, Bouvier C, Assemat P, Gaspar N, Aubert S, Guinebretiere JM, Marie B, Larousserie F, Entz-Werlé N, Pinieux G, Mascard E, Gouin F, Brousset P, Tabone MD, Jimenez M, Le Deley MC, Blay JY, Brugieres L, Piperno-Neumann S, Rédini F.
PMID: 33498676
Cancers (Basel). 2021 Jan 23;13(3). doi: 10.3390/cancers13030423.

Biological and histopathological techniques identified osteoclasts and macrophages as targets of zoledronic acid (ZA), a therapeutic agent that was detrimental for patients in the French OS2006 trial. Conventional and multiplex immunohistochemistry of microenvironmental and OS cells were performed on...

Cite
Gomez-Brouchet A, Gilhodes J, Acker NV, et al. Characterization of Macrophages and Osteoclasts in the Osteosarcoma Tumor Microenvironment at Diagnosis: New Perspective for Osteosarcoma Treatment?. Cancers (Basel). 2021;13(3)doi: 10.3390/cancers13030423.
Gomez-Brouchet, A., Gilhodes, J., Acker, N. V., Brion, R., Bouvier, C., Assemat, P., Gaspar, N., Aubert, S., Guinebretiere, J. M., Marie, B., Larousserie, F., Entz-Werlé, N., Pinieux, G., Mascard, E., Gouin, F., Brousset, P., Tabone, M. D., Jimenez, M., Le Deley, M. C., Blay, J. Y., Brugieres, L., Piperno-Neumann, S., & Rédini, F. (2021). Characterization of Macrophages and Osteoclasts in the Osteosarcoma Tumor Microenvironment at Diagnosis: New Perspective for Osteosarcoma Treatment?. Cancers, 13(3), . https://doi.org/10.3390/cancers13030423
Gomez-Brouchet, Anne, et al. "Characterization of Macrophages and Osteoclasts in the Osteosarcoma Tumor Microenvironment at Diagnosis: New Perspective for Osteosarcoma Treatment?." Cancers vol. 13,3 (2021). doi: https://doi.org/10.3390/cancers13030423
Gomez-Brouchet A, Gilhodes J, Acker NV, Brion R, Bouvier C, Assemat P, Gaspar N, Aubert S, Guinebretiere JM, Marie B, Larousserie F, Entz-Werlé N, Pinieux G, Mascard E, Gouin F, Brousset P, Tabone MD, Jimenez M, Le Deley MC, Blay JY, Brugieres L, Piperno-Neumann S, Rédini F. Characterization of Macrophages and Osteoclasts in the Osteosarcoma Tumor Microenvironment at Diagnosis: New Perspective for Osteosarcoma Treatment?. Cancers (Basel). 2021 Jan 23;13(3). doi: 10.3390/cancers13030423. PMID: 33498676; PMCID: PMC7866157.
Copy Download .nbib Format: NLM
Disease progression in patients with the restrictive and mixed phenotype of Chronic Lung Allograft dysfunction-A retrospective analysis in five European centers to assess the feasibility of a therapeutic trial.

PloS one

Gottlieb J, Verleden GM, Perchl M, Valtin C, Vallee A, Brugière O, Bravo C.
PMID: 34941934
PLoS One. 2021 Dec 23;16(12):e0260881. doi: 10.1371/journal.pone.0260881. eCollection 2021.

BACKGROUND: Chronic Lung Allograft Dysfunction (CLAD) is a major obstacle for long term survival after lung transplantation (LTx). Besides Bronchiolitis Obliterans Syndrome, two other phenotypes of CLAD, restrictive allograft syndrome (RAS) and mixed phenotype, have been described. Trials to...

Cite
Gottlieb J, Verleden GM, Perchl M, et al. Disease progression in patients with the restrictive and mixed phenotype of Chronic Lung Allograft dysfunction-A retrospective analysis in five European centers to assess the feasibility of a therapeutic trial. PLoS One. 2021;16(12):e0260881doi: 10.1371/journal.pone.0260881.
Gottlieb, J., Verleden, G. M., Perchl, M., Valtin, C., Vallee, A., Brugière, O., & Bravo, C. (2021). Disease progression in patients with the restrictive and mixed phenotype of Chronic Lung Allograft dysfunction-A retrospective analysis in five European centers to assess the feasibility of a therapeutic trial. PloS one, 16(12), e0260881. https://doi.org/10.1371/journal.pone.0260881
Gottlieb, Jens, et al. "Disease progression in patients with the restrictive and mixed phenotype of Chronic Lung Allograft dysfunction-A retrospective analysis in five European centers to assess the feasibility of a therapeutic trial." PloS one vol. 16,12 (2021): e0260881. doi: https://doi.org/10.1371/journal.pone.0260881
Gottlieb J, Verleden GM, Perchl M, Valtin C, Vallee A, Brugière O, Bravo C. Disease progression in patients with the restrictive and mixed phenotype of Chronic Lung Allograft dysfunction-A retrospective analysis in five European centers to assess the feasibility of a therapeutic trial. PLoS One. 2021 Dec 23;16(12):e0260881. doi: 10.1371/journal.pone.0260881. eCollection 2021. PMID: 34941934; PMCID: PMC8700042.
Copy Download .nbib Format: NLM
Long-term morbidity and mortality in 2-year hepatoblastoma survivors treated with SIOPEL risk-adapted strategies.

Hepatology international

Illiano M, Colinard M, Taque S, Mallon B, Larue C, Laithier V, Vérité-Goulard C, Sudour-Bonnange H, Faure-Conter C, Coze C, Aerts I, De Maricourt CD, Paillard C, Branchereau S, Brugières L, Fresneau B.
PMID: 34506008
Hepatol Int. 2021 Sep 10; doi: 10.1007/s12072-021-10251-1. Epub 2021 Sep 10.

BACKGROUND AND AIMS: Prognosis of hepatoblastoma patients has increased with cisplatin-based chemotherapy and high-quality resection including liver transplant. Consequently current risk-adapted therapeutic strategy aims to reduce long-term side effects in patients with standard risk disease.METHODS: We report long-term mortality...

Cite
Illiano M, Colinard M, Taque S, et al. Long-term morbidity and mortality in 2-year hepatoblastoma survivors treated with SIOPEL risk-adapted strategies. Hepatol Int. 2021;doi: 10.1007/s12072-021-10251-1.
Illiano, M., Colinard, M., Taque, S., Mallon, B., Larue, C., Laithier, V., Vérité-Goulard, C., Sudour-Bonnange, H., Faure-Conter, C., Coze, C., Aerts, I., De Maricourt, C. D., Paillard, C., Branchereau, S., Brugières, L., & Fresneau, B. (2021). Long-term morbidity and mortality in 2-year hepatoblastoma survivors treated with SIOPEL risk-adapted strategies. Hepatology international, . https://doi.org/10.1007/s12072-021-10251-1
Illiano, M, et al. "Long-term morbidity and mortality in 2-year hepatoblastoma survivors treated with SIOPEL risk-adapted strategies." Hepatology international vol. (2021). doi: https://doi.org/10.1007/s12072-021-10251-1
Illiano M, Colinard M, Taque S, Mallon B, Larue C, Laithier V, Vérité-Goulard C, Sudour-Bonnange H, Faure-Conter C, Coze C, Aerts I, De Maricourt CD, Paillard C, Branchereau S, Brugières L, Fresneau B. Long-term morbidity and mortality in 2-year hepatoblastoma survivors treated with SIOPEL risk-adapted strategies. Hepatol Int. 2021 Sep 10; doi: 10.1007/s12072-021-10251-1. Epub 2021 Sep 10. PMID: 34506008.
Copy Download .nbib Format: NLM
Mineral and Bone Consequences of High Dose Denosumab Therapy to Treat an Aneurysmal Bone Cyst, a Child Case Report.

Frontiers in endocrinology

Del Sindaco G, Berlanga P, Brugières L, Thebault E, Mantovani G, Wicart P, Linglart A.
PMID: 34335473
Front Endocrinol (Lausanne). 2021 Jul 16;12:698963. doi: 10.3389/fendo.2021.698963. eCollection 2021.

Aneurysmal bone cysts (ABCs) are rare benign pseudotumoral bone lesions with potential aggressive behavior due to the extensive destruction of surrounding bone. Traditionally, these tumors were treated with open surgery, but there is more and more a shift to...

Cite
Del Sindaco G, Berlanga P, Brugières L, et al. Mineral and Bone Consequences of High Dose Denosumab Therapy to Treat an Aneurysmal Bone Cyst, a Child Case Report. Front Endocrinol (Lausanne). 2021;12:698963doi: 10.3389/fendo.2021.698963.
Del Sindaco, G., Berlanga, P., Brugières, L., Thebault, E., Mantovani, G., Wicart, P., & Linglart, A. (2021). Mineral and Bone Consequences of High Dose Denosumab Therapy to Treat an Aneurysmal Bone Cyst, a Child Case Report. Frontiers in endocrinology, 12698963. https://doi.org/10.3389/fendo.2021.698963
Del Sindaco, Giulia, et al. "Mineral and Bone Consequences of High Dose Denosumab Therapy to Treat an Aneurysmal Bone Cyst, a Child Case Report." Frontiers in endocrinology vol. 12 (2021): 698963. doi: https://doi.org/10.3389/fendo.2021.698963
Del Sindaco G, Berlanga P, Brugières L, Thebault E, Mantovani G, Wicart P, Linglart A. Mineral and Bone Consequences of High Dose Denosumab Therapy to Treat an Aneurysmal Bone Cyst, a Child Case Report. Front Endocrinol (Lausanne). 2021 Jul 16;12:698963. doi: 10.3389/fendo.2021.698963. eCollection 2021. PMID: 34335473; PMCID: PMC8322664.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 53 entries